{"id":"NCT01797185","sponsor":"Sun Pharma Advanced Research Company Limited","briefTitle":"Safety Study of SPARC1104","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-09","primaryCompletion":"2017-07","completion":"2017-10","firstPosted":"2013-02-22","resultsPosted":"2019-03-12","lastUpdate":"2019-05-03"},"enrollment":375,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Spasticity"],"interventions":[{"type":"DRUG","name":"SPARC1104 modified dose regimen I","otherNames":[]},{"type":"DRUG","name":"SPARC1104 modified dose regimen II","otherNames":[]},{"type":"DRUG","name":"SPARC1104 modified dose regimen III","otherNames":[]}],"arms":[{"label":"SPARC1104 group 1","type":"EXPERIMENTAL"},{"label":"SPARC1104 group 2","type":"EXPERIMENTAL"},{"label":"SPARC1104 group 3","type":"EXPERIMENTAL"}],"summary":"Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis","primaryOutcome":{"measure":"Number of Subjects With Adverse Events","timeFrame":"52 weeks","effectByArm":[{"arm":"SPARC1104 Group 1","deltaMin":129,"sd":null},{"arm":"SPARC1104 Group 2","deltaMin":150,"sd":null},{"arm":"SPARC1104 Group 3","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":162},"commonTop":["Headache","Multiple sclerosis relapse","Muscle spasticity","Urinary tract infection","Muscle spasms"]}}